Today: 17 May 2026
Euronext share price up 4% into weekend: week ahead for ENX stock hinges on ECB signals and German Ifo
22 February 2026
2 mins read

Euronext share price up 4% into weekend: week ahead for ENX stock hinges on ECB signals and German Ifo

Paris, February 22, 2026, 07:06 CET — The market shutters for the session.

  • ENX wrapped up Friday at 127.40 euros, climbing 4% by the close.
  • With European stocks ending on a risk-on note, investors now shift their focus to euro zone data and signals from the ECB.
  • Investors are watching Euronext’s full-year results, a proposed dividend, buyback plans, and the scheduled March 14 clearing migration.

Euronext finished Friday at 127.40 euros, adding 4% for the day. The last trade hit at 17:37 CET. Ahead of Monday, traders are still chewing over a flurry of data and policy cues as the exchange operator lines up for the next session.

Euronext lives off volatility. Its earnings swell when investors ramp up trading — whether that’s equities, bonds, or derivatives — as fee income flows in, but volumes often lurch as interest rate expectations shift.

The broader market backdrop can’t be ignored. European stocks finished the week at all-time highs after the U.S. Supreme Court tossed out major American tariffs, though some market watchers cautioned that the decision leaves investors grappling with fresh uncertainty. “It has good elements to it and slightly less good elements, because it will increase this legendary uncertainty that markets, of course, always fear,” said IG’s Chris Beauchamp. Reuters

Friday’s survey numbers handed markets a clearer tailwind. The HCOB flash composite Purchasing Managers’ Index (PMI) came in at 51.9 for February — anything above 50 signals growth. Manufacturing returned to expansion, and firms lifted prices only slightly, bolstering bets that the ECB can leave rates on hold. “February’s flash PMIs support the view that activity in the euro zone economy is growing at a reasonable pace, led by a pick-up in Germany,” said Andrew Kenningham at Capital Economics. Reuters

Euronext’s latest figures gave investors plenty to chew on. Fourth-quarter revenue hit 456.4 million euros, a jump of almost 10% from last year. Core profit (EBITDA) landed at 275 million euros, up 8.9%. The company plans to put a 321.5 million euro dividend proposal in front of shareholders at the annual meeting in May. CEO Stéphane Boujnah zeroed in on defence IPOs—“The defence sector is the sweet spot for IPOs”—and kept pushing for industry consolidation: “If you want to compete against NYSE and Nasdaq, you don’t create another Playmobil exchange.” Reuters

Euronext wrapped up a 250 million euro share buyback for the year, taking in roughly 1.97 million shares at an average 127.03 euros apiece. The company plans to cancel those shares, pending a green light from shareholders. Euronext left its 2026 cost target unchanged—still looking at about 770 million euros in underlying expenses, not counting depreciation and amortisation. And it locked in March 14 for the shift of Nordic power futures open interest—outstanding positions—from Nasdaq Clearing over to Euronext Clearing.

Not much on the immediate policy docket, but markets are keeping an eye out. The ECB Governing Council gathers on Feb. 25—this one’s not about rates, just a non-monetary policy session. Their next call on monetary policy isn’t until March 18-19, capped off with the usual press conference.

ECB chatter kept going through the weekend. On Saturday, policymaker Fabio Panetta flagged “significant” inflation risks, both up and down. “The main one is the trend in imports from China,” he said. Since early 2024, euro zone imports from China are up 27% by volume, while prices dropped 8%. Panetta pointed to new staff projections coming in March as the policy touchstone. Reuters

ENX holders are weighing if steadier growth is enough to counter inflation jitters — and whether that keeps volumes moving. Calmer markets tend to sap trading, and Euronext’s share price responds fast.

New listings and demand for risk capital can move the needle, especially when equities are climbing and rates seem steady. That’s when risk appetite usually perks up.

Still, things can reverse quickly. Should the tariff clouds linger without much drama and rate expectations steady, volatility might fade, and trading could thin out. A steeper market drop, though, would challenge investors’ nerves and possibly force IPO hopefuls to hold back.

First up, Germany’s ifo business climate index is set for release Monday, Feb. 23, landing at 10:30 CET. That’s the next sentiment pulse following the PMI rebound.

Stock Market Today

  • FirstEnergy Valuation Under Review Amid Conflicting Fair Value Estimates
    May 16, 2026, 10:33 PM EDT. FirstEnergy (FE) shares fell 12.5% over 30 days to $43.82, prompting investor scrutiny. The utility, valued at $25.3 billion, benefits from a $28 billion infrastructure modernization plan aimed at boosting reliability and earnings. Analysts see potential undervaluation with a fair value near $53.23, reflecting expected growth. However, a discounted cash flow (DCF) model suggests a more conservative fair value of $28.75, highlighting concerns over cash flow and funding risks. This divergence marks a critical juncture for investors weighing regulatory impacts and capital needs against growth prospects in the power transmission sector.

Latest articles

Joby Aviation Slides Monday With Air-Taxi in Focus

Joby Aviation Slides Monday With Air-Taxi in Focus

17 May 2026
Joby Aviation shares closed Friday at $10.36, down 2.6% for the day and 4.7% for the week. CEO JoeBen Bevirt-linked trusts sold over 421,000 shares under a preset 10b5-1 plan, filings showed. The stock traded between $10.04 and $10.58 during a volatile week. Broader markets and eVTOL sector peers also declined.
ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

17 May 2026
ImmunityBio closed at $7.97 Friday, down 2.2% after announcing exclusive U.S. rights to Japan BCG Laboratory’s Tokyo-172 strain for bladder cancer therapy. The Tokyo strain remains investigational in the U.S. and is not FDA-approved. Nasdaq was closed for the weekend; the next trading session is Monday. ImmunityBio’s Q1 product revenue rose to $44.2 million with $380.9 million in cash and securities.
Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

17 May 2026
Infleqtion Inc. shares fell 10.95% to $12.44 Friday, capping a rough week for quantum tech stocks. The company reported a first-quarter net loss of $30.3 million on $9.5 million in revenue, with 85% from government contracts. Infleqtion launched a new RF sensing platform and raised its 2026 revenue outlook, but warned of continued operating losses.
Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

17 May 2026
Synopsys shares fell 1.49% Friday to $502.42, ending the week down 2.72% amid a broad tech selloff and news that Coatue Management cut its stake by 54%. The Nasdaq Composite dropped 1.54% Friday, while the Philadelphia semiconductor index slid 4%. Synopsys will report fiscal Q2 results after the market closes on May 27. Wells Fargo and Citigroup raised their price targets for the stock earlier in the week.
Salesforce stock (CRM) steadies, but Wall Street trims targets again ahead of Feb. 25 results
Previous Story

Salesforce stock (CRM) steadies, but Wall Street trims targets again ahead of Feb. 25 results

Plug Power stock dips before the bell as tariff jitters and dilution fears linger
Next Story

Plug Power stock dips before the bell as tariff jitters and dilution fears linger

Go toTop